TOP2A and prostate cancer: Given that neither TOP2A nor EZH2 commonly harbor somatic changes in prostate cancer that can be detected by DNA sequencing, this highlights the potential of 5hmC-seq to add to current analyses of cfDNA in advanced cancers.